VivoSeq
Other

Uterine Leiomyoma

16

Pipeline Programs↗

1

Active Trials↗

8

Companies Involved↗

Uterine leiomyoma is an emerging landscape with 16 programs across 8 companies. The most active players are Novartis, Endo Pharmaceuticals, Danco. 4 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

64/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 1Endo Pharmaceuticals logo

Endo Pharmaceuticals

1 program

Phase 1D

Danco

1 program

Phase 2W

Watson Pharmaceuticals

1 program

Phase 3Bayer logo

Bayer

1 program

ApprovedE

Eastern Cooperative Oncology Group

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

15

clinical trials

Completed7 · 47%
Unknown status3 · 20%
Withdrawn2 · 13%
Terminated2 · 13%
Recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

Effects of Simvastatin on Uterine Leiomyoma Size
Recruiting·JJohns Hopkins University·Phase 2·NCT03400826·60 enrolled
PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata
Completed·PPregLem SA·Phase 3·NCT01642472·64 enrolled
PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata
Completed·PPregLem SA·Phase 3·NCT01156857·209 enrolled
PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata
Completed·PPregLem SA·Phase 3·NCT01629563·451 enrolled
Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)
Completed·AAdvance Biofactures Corporation·Phase 1·NCT02889848·15 enrolled
Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)
Completed·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00332033·32 enrolled
Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma
Completed·—·Phase 2/3·NCT06115408·40 enrolled
PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)
Completed·PPregLem SA·Phase 3·NCT01252069·132 enrolled
Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin
Terminated·UUniversity of Sao Paulo·Phase 4·NCT01738724·14 enrolled
A Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas
Terminated·PPoitiers University Hospital·Phase 2·NCT00219778·20 enrolled
Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma
Withdrawn·WWatson Pharmaceuticals·Phase 3·NCT01553123
Aromatase Inhibitors for Treatment of Uterine Leiomyomas
Withdrawn·—·Phase 1·NCT00945360
The Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Women
Unknown status·RRoyan Institute·Phase 3·NCT03134157·60 enrolled
Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma
Unknown status·UUniversity Magna Graecia·Phase 4·NCT02361879·146 enrolled
Management of Uterine Leiomyomata and Adenomyosis
Unknown status·—·N/A·NCT05153928·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)